Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic

被引：223

作者：

O'Bryant, Sid E. ^{[1
]}

Mielke, Michelle M. ^{[2
,3
]}

Rissman, Robert A. ^{[4
]}

Lista, Simone ^{[5
,6
,7
,8
]}

Vanderstichele, Hugo ^{[9
]}

Zetterberg, Henrik ^{[10
,11
,12
]}

Lewczuk, Piotr ^{[13
,14
,15
]}

Posner, Holly ^{[16
]}

Hall, James ^{[1
]}

Johnson, Leigh ^{[1
]}

Fong, Yiu-Lian ^{[17
]}

Luthman, Johan ^{[18
]}

Jeromin, Andreas ^{[19
]}

Batrla-Utermann, Richard ^{[20
]}

Villarreal, Alcibiades ^{[21
,22
]}

Britton, Gabrielle ^{[21
,22
]}

Snyder, Peter J. ^{[23
,24
]}

Henriksen, Kim ^{[25
]}

Grammas, Paula ^{[26
]}

Gupta, Veer ^{[27
]}

Martins, Ralph ^{[27
]}

Hampel, Harald ^{[5
,6
,7
,8
]}

机构：

[1] Univ North Texas, Inst Hlth Aging, Hlth Sci Ctr, Ft Worth, TX 76107 USA

[2] Mayo Clin, Dept Neurol, Rochester, MN USA

[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA

[4] UCSD Sch Med, Dept NeuroSci, Alzheimers Dis Cooperat Study, La Jolla, CA USA

[5] AXA Res Fund, Paris, France

[6] UPMC Chair, Paris, France

[7] Univ Paris 06, Sorbonne Univ, Hosp Pitie Salpetriere, Dept Neuol,IM2A, Paris, France

[8] Univ Paris 06, Sorbonne Univ, Hosp Pitie Salpetriere, Inst Cerveau & Moelle Epiniere ICM, Paris, France

[9] ADx NeuroSci NV, Ghent, Belgium

[10] Sahlgrens Acad, Inst Neurosci & Physiol, Clin Neurochem Lab, Molndal, Sweden

[11] Univ Gotenburg, Molndal, Sweden

[12] UCL Inst Neurol, London, England

[13] Univ Klinikum Erlangen, Dept Psychiat & Psychotherapy, Erlangen, Germany

[14] Friedrich Alexander Univ Erlangen Nurnberg, Erlangen, Germany

[15] Med Univ Bialystok, Dept Neumdegenerat Diagnost, Bialystok, Poland

[16] Pfizer Inc, New York, NY USA

[17] Johnson & Johnson, London Innovat Ctr London, London, England

[18] Clin Neurosci Eisai, Neurosci Clin Dev, Woodcliff Lake, NJ USA

[19] Quanterix Corp, Lexington, MA USA

[20] Roche Diagnost Int Ltd, Rotkreuz, Switzerland

[21] Inst Invest Cient & Serv Alta Tecnol INDICASAT AI, Ctr Neurociencias, Ciudad Del Saber, Panama

[22] Inst Invest Cient & Serv Alta Tecnol INDICASAT AI, Unidad Invest Clin, Ciudad Del Saber, Panama

[23] Brown Univ, Rhode Isl Hosp, Dept Neurol, Providence, RI 02903 USA

[24] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA

[25] Nord Biosci Biomarkers & Res, Neurodegenerat Dis, Herlev, Denmark

[26] Univ Rhode Isl, George & Anne Ryan Inst Neurosci, Kingston, RI 02881 USA

[27] Edith Cowan Univ, Fac Hlth Engn & Sci, Ctr Excellence Alzheimers Dis Res & Care, Sch Med Sci, Joondalup, WA, Australia

来源：

ALZHEIMERS & DEMENTIA | 2017年 / 13卷 / 01期

基金：

美国国家卫生研究院;

关键词：

Alzheimer's disease; Biomarker; Blood; Diagnosis; Cerebrospinal fluid; Imaging; Context of use; DIAGNOSTIC-TOOLS; DRUG DEVELOPMENT; ASSAY PLATFORMS; PLASMA; TAU; MARKERS; CHEMOTHERAPY; PROGRESSION; VALIDATION; CANDIDATES;

D O I：

10.1016/j.jalz.2016.09.014

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patient acceptance. Despite these advantages and increased research efforts, the field has been hampered by lack of reproducibility and an unclear path for moving basic discovery toward clinical utilization. Here we reviewed the recent literature on blood-based biomarkers in AD to provide a current state of the art. In addition, a collaborative model is proposed that leverages academic and industry strengths to facilitate the field in moving past discovery only work and toward clinical use. Key resources are provided. This new public-private partnership model is intended to circumvent the traditional handoff model and provide a clear and useful paradigm for the advancement of biomarker science in AD and other neurodegenerative diseases. (C) 2016 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

引用

页码：45 / 58

页数：14

共 68 条

[1]

Andreasson Ulf, 2016, Alzheimers Dement (Amst), V3, P98, DOI 10.1016/j.dadm.2016.05.005

[2]

[Anonymous], 2015, GERONTOLOGICAL SOC A

[3]

[Anonymous], 2013, The Economist

[4] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework [J].

Atkinson, AJ ;

Colburn, WA ;

DeGruttola, VG ;

DeMets, DL ;

Downing, GJ ;

Hoth, DF ;

Oates, JA ;

Peck, CC ;

Schooley, RT ;

Spilker, BA ;

Woodcock, J ;

Zeger, SL .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (03) :89-95

[5] Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases (vol 91, pg 56, 2016) [J].

Bacioglu, Mehtap ;

Maia, Luis F. ;

Preische, Oliver ;

Schelle, Juliane ;

Apel, Anja ;

Kaeser, Stephan A. ;

Schweighauser, Manuel ;

Eninger, Timo ;

Lambert, Marius ;

Pilotto, Andrea ;

Shimshek, Derya R. ;

Neumann, Ulf ;

Kahle, Philipp J. ;

Staufenbiel, Matthias ;

Neumann, Manuela ;

Maetzler, Walter ;

Kuhle, Jens ;

Jucker, Mathias .

NEURON, 2016, 91 (02) :494-496

[6] Plasma Amyloid Beta-42 Independently Predicts Both Late-Onset Depression and Alzheimer Disease [J].

Blasko, Imrich ;

Kemmler, Georg ;

Jungwirth, Susanne ;

Wichart, Ildiko ;

Krampla, Wolfgang ;

Weissgram, Silvia ;

Jellinger, Kurt ;

Tragl, Karl Heinz ;

Fischer, Peter .

AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2010, 18 (11) :973-982

[7] EVOLUTION OF Aβ42 AND Aβ40 LEVELS AND Aβ42/Aβ40 RATIO IN PLASMA DURING PROGRESSION OF ALZHEIMER'S DISEASE: A MULTICENTER ASSESSMENT [J].

Blennow, K. ;

De Meyer, G. ;

Hansson, O. ;

Minthon, L. ;

Wallin, A. ;

Zetterberg, H. ;

Lewczuk, P. ;

Vanderstichele, H. ;

Vanmechelen, E. ;

Kornhuber, J. ;

Wiltfang, J. .

JOURNAL OF NUTRITION HEALTH & AGING, 2009, 13 (03) :205-208

[8]

Bowsher RR, 2012, BIOANALYSIS, V4, P2427, DOI [10.4155/BIO.12.238, 10.4155/bio.12.238]

[9] Insights in the application of research-grade diagnostic kits for biomarker assessments in support of clinical drug development: Bioanalysis of circulating concentrations of soluble receptor activator of nuclear factor κB ligand [J].

Bowsher, Ronald R. ;

Sailstad, Jeffrey M. .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2008, 48 (05) :1282-1289

[10] A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study [J].

Burnham, S. C. ;

Faux, N. G. ;

Wilson, W. ;

Laws, S. M. ;

Ames, D. ;

Bedo, J. ;

Bush, Ai ;

Doecke, J. D. ;

Ellis, K. A. ;

Head, R. ;

Jones, G. ;

Kiiveri, H. ;

Martins, R. N. ;

Rembach, A. ;

Rowe, C. C. ;

Salvado, O. ;

Macaulay, S. L. ;

Masters, C. L. ;

Villemagne, V. L. .

MOLECULAR PSYCHIATRY, 2014, 19 (04) :519-526

← 1 2 3 4 5 6 7 →